New acridinone derivative with trypanocidal activity.

M, Tompkins LS, editors. Campylobacter jejuni: current status and future trends. Washington, DC: American Society for Microbiology; 1992. [2] Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007;44:681–8. [3] National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. 2nd ed. Approved standard M31-A2. Wayne, PA: NCCLS; 2002. [4] Pasquali F, Manfreda G. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Vet Microbiol 2007;119:304–10. [5] Zirnstein G, Li Y, Swaminathan B, Angulo F. Ciprofloxacin resistance inCampylobacter jejuni isolates: detection ofgyrA resistance mutations by mismatch amplification mutation assay PCR and DNA sequence analysis. J Clin Microbiol 1999;37:3276–80. [6] National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. M100-S14. Wayne, PA: NCCLS; 2004. [7] Payot S, Cloeckaert A, Chaslus-Dancla E. Selection and characterisation of fluoroquinolone-resistant mutants of Campylobacter jejuni using enrofloxacin. Microb Drug Resist 2002;8: 335–43. [8] Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, et al. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1993;37:2193–9. [9] Anadón A, Martı́nez-Larrañaga MR, Iturbe J, Martı́nez MA, Dı́az MJ, Frejo MT, et al. Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. Res Vet Sci 2001;71:101–9. 10] Cuisinaud G, Ferry N, Pozet N, Zech PY, Sassard J. Nalidixic acid kinetics in renal insufficiency. Br J Clin Pharmacol 1982;14:489–93.